Recruiting
Tier Palliative Care For Patients With Advanced Heart Failure or Cancer
NCT07391956· Icahn School of Medicine at Mount Sinai· Source
Contact: Laura Gelfman, MD, MPH
Recruiting
Vestibular Innovation in Pain 2
NCT07423377· Icahn School of Medicine at Mount Sinai· Source
Contact: Michael Kaplan (principal investigator)
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· Phase 3· National Cancer Institute (NCI)· Source
Contact: Stephanie V. Blank (principal investigator)
Recruiting
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NCT06686771· Phase 3· Canadian Cancer Trials Group· Source
Contact: Robert M. Samstein (principal investigator)
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Dmitriy Zamarin (principal investigator)
Recruiting
Validating CGM for GDM
NCT06858787· Icahn School of Medicine at Mount Sinai· Source
Contact: Shelly Thai, MD
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: Karyn A. Goodman (principal investigator)
Not yet recruiting
ExosomeDx in MRI-negative Men With High PSA
NCT06966089· Icahn School of Medicine at Mount Sinai· Source
Contact: Craig Nobert (sub-investigator)
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246· Phase 3· Joseph Broderick, MD· Source
Contact: John W Liang, MD
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Recruiting
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
NCT06999122· EMVision Medical Devices Ltd· Source
Contact: Megha Dhillon
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· Phase 3· NRG Oncology· Source
Contact: Stephanie V. Blank (principal investigator)
Recruiting
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371· Phase 2· Cytokinetics· Source
Contact: Cytokinetics MD
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418· Cleerly, Inc.· Source
Contact: Waqas A Malick, MD
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· Phase 3· NRG Oncology· Source
Contact: Daniel R. Dickstein (principal investigator)
Active, not recruiting
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
NCT05836584· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487· Endotronix, Inc.· Source
Contact: Sajiny John
Recruiting
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Karyn A. Goodman (principal investigator)
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Melanie W. Kier (principal investigator)
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212· Phase 3· NRG Oncology· Source
Active, not recruiting
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT04929041· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT04929028· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· Phase 2/3· NRG Oncology· Source
Contact: Peter S. Kozuch (principal investigator)
Active, not recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883· Phase 3· Joseph Broderick, MD· Source
Recruiting
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT05095207· Phase 1/2· Icahn School of Medicine at Mount Sinai· Source
Contact: Laura A Fiedler, MPH
Recruiting
Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder
NCT05160129· Icahn School of Medicine at Mount Sinai· Source
Contact: Martijn Figee
Enrolling by invitation
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT05368038· Albert Einstein College of Medicine· Source
Active, not recruiting
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141· Phase 3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Bobby Liaw (principal investigator)
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: Stephanie V. Blank (principal investigator)
Active, not recruiting
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04214067· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046· Phase 3· Yale University· Source
Contact: Neha Dangayach, MD
Active, not recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
NCT03728985· W.L.Gore & Associates· Source
Active, not recruiting
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Vaginal Microbiome Exposure and Immune Responses in C-section Infants
NCT03567707· Early phase 1· National Institute of Allergy and Infectious Diseases (NIAID)· Source
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928· SWOG Cancer Research Network· Source
Contact: Amy D. Tiersten (principal investigator)
Active, not recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
NCT03304080· Phase 1/2· Icahn School of Medicine at Mount Sinai· Source
Active, not recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771· Phase 2· NRG Oncology· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Showing 50 of 55.